DYN
Dyne Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.87B
P/E Ratio
—
EPS
$-3.15
Beta
1.08
52W High
$25.00
52W Low
$8.06
50-Day MA
$18.25
200-Day MA
$17.15
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.19
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a muscle disease company, is a biotechnology company focused on advancing therapeutics for genetically-derived muscle diseases in the United States. The company is headquartered in Waltham, Massachusetts.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-468.99M |
| Operating Margin | 0.00% |
| Return on Equity | -58.90% |
| Return on Assets | -32.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $5.89 |
| Price-to-Book | 3.32 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -8.87 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $165.31M |
| Float | $164.74M |
| % Insiders | 0.28% |
| % Institutions | 115.41% |
Historical Volatility
HV 10-Day
72.12%
HV 20-Day
65.08%
HV 30-Day
58.98%
HV 60-Day
74.95%
HV Rank
30.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($38.25 target)
3
Strong Buy11
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026